Role of CCL2 in Alcoholic Liver Diseases

This study has been completed.

Sponsor:

Information provided by:

Erasme University Hospital

ClinicalTrials.gov Identifier:

NCT01128010

First received: May 20, 2010

Last updated: NA

Last verified: December 2002

History: No changes posted

Tracking Information
First Received Date ^ICMJE	May 20, 2010
Last Updated Date	May 20, 2010
Start Date ^ICMJE	Not Provided
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Role of CCL2 in Alcoholic Liver Diseases
Official Title ^ICMJE	Not Provided
Brief Summary	Immune dysregulations, including cytokines and chemokines secretions occurs in alcoholic liver disease. Serum levels and liver expression of CCL2 are increased in patients with alcoholic hepatitis but the role of this chemokine in the pathogenesis of alcoholic liver disease is nevertheless unknown. The aim of the study is to analyze plasma level and liver expression of CCL2 and their relation with liver disease severity and inflammatory infiltrate in our cohort of alcoholic patients. We studied also the association between -2518 CCL2 polymorphism and the severity of alcoholic liver disease.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Case Control Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Probability Sample
Study Population	Consecutive patients undergoing transjugular liver biopsy for alcoholic liver disease will be include in the study to measure plasma levels and hepatic expression of CCL2. We determine also the rs1024611 polymorphism of these patients. All these parameters are correlated to severity of the disease. The frequency of the presence of this polymorphism was also compared to a population of healthy subjects.
Condition ^ICMJE	Alcoholic Liver Disease
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	alcoholic liver disease alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution controls Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	Not Provided
Completion Date	Not Provided
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	ALD patients Inclusion Criteria: Excess alcohol intake Abnormality of liver biopsy compatible with alcoholic aetiology Caucasian ethnicity Exclusion Criteria: Presence of any other chronic liver disease co-infection with HIV Controls Inclusion criteria Caucasian ethnicity presence of a disease
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT01128010
Other Study ID Numbers ^ICMJE	DD-CCL2
Has Data Monitoring Committee	Not Provided
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Erasme University Hospital
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Erasme University Hospital
Verification Date	December 2002
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top